<DOC>
	<DOCNO>NCT00591084</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ginsenoside-Rd acute ischemic stroke .</brief_summary>
	<brief_title>Ginsenoside-Rd Acute Ischemic Stroke</brief_title>
	<detailed_description>A major contributor brain injury stroke disordered inward flow Ca2+ toxic accumulation nervous system follow cerebral ischemia . Ginsenoside-Rd , purify component total saponin Panax notoginseng , molecular formula C48H82O18â€¢3H2O molecular weight 1001.2 . Ginsenoside-Rd show inhibit receptor-operated Ca2+ influx receptor-and-store-operated Ca2+ channel ( ROCC ) , attenuate oxidative stress stroke , reduce size cerebral infarction preserve brain function animal model acute ischemic stroke .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>18 75 year first episode onset admission within 72 hour NIHSS scores:5~22 intracranial pathology ( e.g. , tumor , infection ) neurologic psychiatric disease coexist condition limit life expectancy significant drug alcohol misuse highgrade carotid artery stenosis surgery plan pregnant nursing participate clinical trial investigational drug device within past 3 month unlikely available followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>randomize trial</keyword>
	<keyword>ischemic stroke</keyword>
	<keyword>Ginsenoside-Rd</keyword>
</DOC>